FDA Approves Expanded Indication for Bristol-Myers Squibb’s Orencia

The FDA has approved Bristol-Myers Squibb’s subcutaneous Orencia administration option for use in patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis.

The prefilled syringe offers the option of Orencia treatment that can be administered at home.

In 2008, Orencia IV was approved for use in patients 6 years of age and older with moderately to severely active polyarticular JIA.